Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer

Next Previous
Search
Trial Profile

Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ODM 209 (Primary) ; Glucocorticoids; Mineralocorticoids
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Male breast cancer; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms STESIDES
  • Sponsors Orion Pharma

    • Most Recent Events

    • 04 Jun 2024 Results assessing data ffrom the first-in-man phase I STESIDES study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 31 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2023 This study has been completed in Italy, accoding to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top